



## OPEN ACCESS

EDITED AND REVIEWED BY  
Tony D. James,  
University of Bath, United Kingdom

\*CORRESPONDENCE  
Yong Yao,  
✉ yaoyong1986@ntu.edu.cn

RECEIVED 10 February 2025  
ACCEPTED 17 February 2025  
PUBLISHED 05 March 2025

CITATION  
Yao Y, Huo G and Zhao R (2025) Editorial:  
Supramolecular cancer therapeutic  
biomaterials-volume II.  
*Front. Chem.* 13:1574334.  
doi: 10.3389/fchem.2025.1574334

COPYRIGHT  
© 2025 Yao, Huo and Zhao. This is an open-  
access article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in this  
journal is cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Editorial: Supramolecular cancer therapeutic biomaterials-volume II

Yong Yao<sup>1\*</sup>, Guifei Huo<sup>2</sup> and Ruibo Zhao<sup>3</sup>

<sup>1</sup>School of Chemistry and Chemical Engineering, Nantong University, Nantong, China, <sup>2</sup>Department of Chemistry, National University of Singapore, Singapore, Singapore, <sup>3</sup>Department of Materials, Imperial College London, London, United Kingdom

## KEYWORDS

supramolecular chemistry, metal-organic framework, dynamic interactions, biomaterials, cell imaging

## Editorial on the Research Topic

### Supramolecular cancer therapeutic biomaterials-volume II

Supramolecular cancer therapeutic biomaterials are a promising material for cancer treatment (Lv et al., 2022; Zhang H. et al., 2022; Goor et al., 2017). These biomaterials are designed and prepared based on supramolecular chemistry principles (Zhang X. et al., 2022; Chen et al., 2023). Through intermolecular non-covalent forces, they form assemblies with specific properties and complex structures (Klawe et al., 2024; Wang J. et al., 2022). These materials have several advantages in the process of cancer treatment. First, they can be precisely designed to specifically target cancer cells and reduce damage to healthy tissues (Tang et al., 2024; Webber et al., 2016; Wang et al., 2022b). By combining targeting motifs or using stimulus-responsive elements, they can be selectively enriched at the tumor site (Zhang et al., 2023; Hazarika and Singh, 2023; Brito et al., 2021.).

Supramolecular cancer therapeutic biomaterials can also be designed to load and release anticancer drugs in a controllable manner (Mann et al., 2018; Wang et al., 2022c). This enables continuous drug delivery, improves therapeutic effects, and minimizes toxic side effects at the same time (Yang et al., 2022; Wu et al., 2018). In addition, some of these biomaterials can be triggered by external stimuli such as light, heat, or magnetic fields, thereby enabling targeted activation of therapeutic agents (Zhou et al., 2024; Guo et al., 2020). Interestingly, supramolecular biomaterials can exhibit unique properties such as self-assembly, reversible interactions, and adjustable mechanical properties (Cui et al., 2019; Shi et al., 2022). This flexibility allows the design of multifunctional platforms that can combine different treatment methods such as chemotherapy, photothermal therapy, photodynamic therapy, and multimodal synergistic therapy (Wen et al., 2024; Deiser et al., 2023). In this context, we organized the Research Topic of “Supramolecular Cancer Therapeutic Biomaterials” in 2022 and published 8 important articles, showing the latest research results in this field (Yao et al., 2023). Due to the importance and popularity of this Research Topic, we now organize the second volume on this topic. Here, we briefly introduce the research work of this new topic.

Hepatocellular carcinoma (HCC) has the fourth highest death rate among all cancer types worldwide. Programmed cell death (PCD) is a key biological mechanism for controlling cancer progression, tumor expansion and metastasis. In addition, the Tumor microenvironment (TME) is critical in influencing Overall survival (OS) and

immune response to immunotherapy interventions. From a multi-omics perspective, the combination of PCD and TME helps predict survival and response to immunotherapy in patients with liver cancer. Liu et al. analyzed changes in the PCD and TME classifiers used to classify liver cancer patients into two subgroups (high PVD-low TME and low PVD-high TME). Next, they compared Tumor somatic mutation (TMB), immunotherapy response, and functional annotation between the two groups. Finally, Western blot (WB) was performed. Immunohistochemistry (IHC) was assessed on the Human Protein Map (HPA). In the PCD-TME classifier, 23 PCD-related genes and three immune cell types were identified. Using this model, patients' prognosis and response to treatment can be accurately predicted. The results of this study provide a new tool for the clinical management of patients with hepatocellular carcinoma and help develop accurate treatment strategies for these patients.

Fluorescence imaging in the near-infrared-II region has the advantages of centimeter-scale tissue penetration and micron-scale spatial resolution, which has sparked interest in visualizing the lymphatic system. Jin et al. prepared HA@ICG nanoparticles based on the NIR-II fluorescence characteristics of ICG, which inhibited the  $\pi$ - $\pi$  stacking between ICG molecules, had an ideal particle size and surface modification, good imaging duration and resolution, and could assess local microcirculation. *In vitro* and *in vivo* studies demonstrated that it had excellent photostability, biosafety and visualization ability of the lymphatic system, and was expected to be used in the clinic (Zhang et al.). However, further research was needed in the validation of disease models and the imaging of deep-seated lymphatic tissues.

In a research paper, Prof. Wang and coworkers proposed a metal-organic framework (MOF)-based nano-platform for mitochondrial-targeted CO gas therapy and drug combination therapy. They designed a thiol-functionalized MOF (UiO-66-SH) and combined it with the drug resveratrol (RES) to form a UiO@FeCO@RES nano-platform. The platform is capable of triggering decomposition by ATP within tumor cells, releasing RES and generating CO gas, achieving synergistic anti-cancer effects by inhibiting ATPase and disrupting mitochondrial function. Experimental results show that the nano-platform can effectively target mitochondria and release CO gas in response to ROS, significantly enhancing the killing effect on cancer cells (Wang et al.). This strategy of combining gas therapy and drug therapy provides new ideas for cancer treatment.

In a mini-review paper, Fukuhara et al. focuses on the application progress of dynamic and stimuli-responsive supramolecular chemosensors in cancer detection, with particular attention to the external stimulus of solution-state hydrostatic pressure and its role in biological systems. Focusing on the mechanical force of hydrostatic pressure, it was found in HeLa cells that it regulates the influx of  $\text{Ca}^{2+}$  through the piezo ion channel, mainly affecting the intracellular pathway, and the cells

have a dynamic mechanism to restore the original state of the channel. These findings suggest the importance of dynamic and stimuli-responsive supramolecular chemosensors in biological systems (Matsumoto et al.). The different pressure-responsive characteristics of peptide scaffolds can provide ideas for the development of new supramolecular imaging reagents and promote the development of future mechanobiology.

In summary, we highly value the endeavors, understandings, and outlooks of every contributor to the domain of supramolecular cancer therapeutic biomaterials. We sincerely hope that this issue can offer a perspective on applying supramolecular chemistry to address particular biomedical issues and encourage in-depth research within this field.

## Author contributions

YY: Writing-original draft, Writing-review and editing. GH: Writing-review and editing. RZ: Writing-original draft, Writing-review and editing.

## Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. We acknowledge financial support by the National Natural Science Foundation of China (No. 22007052), the Natural Science Foundation of Jiangsu Province (No. BK20190917).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

Brito, A., Kassem, S., Reis, R. L., Ulijn, R. V., Pires, R. A., and Pashkuleva, I. (2021). Carbohydrate amphiphiles for supramolecular biomaterials: design, self-assembly, and applications. *Chem* 7, 2943–2964. doi:10.1016/j.chempr.2021.04.011

Chen, T., Wang, J., Tang, R., Huang, Y., Zhao, Q., and Yao, Y. (2023). An amphiphilic [2]biphenyl-extended pillar[6]arene: synthesis, controllable self-assembly in water and application in cell-imaging. *Chin. Chem. Lett.* 34, 108088. doi:10.1016/j.ccl.2022.108088

- Cui, Y.-H., Deng, R., Li, Z., Du, X. S., Jia, Q., Wang, X. H., et al. (2019). Pillar[5]arene pseudo[1]rotaxane-based redox-responsive supramolecular vesicles for controlled drug release. *Mater. Chem. Front.* 3, 1427–1432. doi:10.1039/C9QM00237E
- Deiser, S., Drexler, M., Moreno-Alcantar, G., Irl, M., Schmidt, C., Günther, T., et al. (2023). Synthesis of <sup>177</sup>Lu-labeled, somatostatin-2 receptor-targeted metalla-assemblies: challenges in the design of supramolecular radiotherapeutics. *Inorg. Chem.* 62, 20710–20720. doi:10.1021/acs.inorgchem.3c02090
- Goor, O. J. G. M., Hendrikse, S. I. S., Dankers, P. Y. W., and Meijer, E. M. (2017). From supramolecular polymers to multi-component biomaterials. *Chem. Soc. Rev.* 46, 6621–6637. doi:10.1039/C7CS00564D
- Guo, S., Huang, Q., Chen, Y., Wei, J., Zheng, J., Wang, L., et al. (2020). Synthesis and bioactivity of guanidinium-functionalized pillar[5]arene as a biofilm disruptor. *Angew. Chem. Int. Ed.* 60, 618–623. doi:10.1002/anie.202013975
- Hazarika, B., and Singh, V. P. (2023). Macrocyclic supramolecular biomaterials in anti-cancer therapeutics. *Chin. Chem. Lett.* 34, 108220. doi:10.1016/j.ccl.2023.108220
- Klawa, S. J., Lee, M., Riker, K. D., Jian, T., Wang, Q., Gao, Y., et al. (2024). Uncovering supramolecular chirality codes for the design of tunable biomaterials. *Nat. Commun.* 15, 788. doi:10.1038/s41467-024-45019-2
- Lv, Q., Ma, B., Li, W., Fu, G., Wang, X., and Xiao, Y. (2022). Nanomaterials-mediated therapeutics and diagnosis strategies for myocardial infarction. *Front. Chem.* 10, 943009. doi:10.3389/fchem.2022.943009
- Mann, J. L., Yu, A. C., Agmon, G., and Appel, E. A. (2018). Supramolecular polymeric biomaterials. *Biomater. Sci.* 6, 10–37. doi:10.1039/C7BM00780A
- Shi, B., Qin, P., Chai, Y., Qu, W. J., Shanguan, L., Lin, Q., et al. (2022). An organoplatinum(II) metallacycle-based supramolecular amphiphile and its application in enzyme-responsive controlled release. *Inorg. Chem.* 61, 8090–8095. doi:10.1021/acs.inorgchem.2c00978
- Tang, R., Zhou, L., Dai, Y., Wang, Y., Cai, Y., Chen, T., et al. (2024). Polydopamine modified by pillar[5]arene *in situ* for targeted chemo-photothermal cancer therapy. *Chem. Commun.* 60, 1160–1163. doi:10.1039/D3CC04196D
- Wang, J., Wang, D., Cen, M., Jing, D., Bei, J., Huang, Y., et al. (2022a). GOx-assisted synthesis of pillar[5]arene based supramolecular polymeric nanoparticles for targeted/synergistic chemo-chemodynamic cancer therapy. *J. Nanobiotechnol.* 20, 33. doi:10.1186/s12951-021-01237-0
- Wang, Y., Tang, R., Wang, D., Wang, J., Huang, Y., Ding, Y., et al. (2022c). Platinum(II)-Metallaclip-Based theranostics for cell imaging and synergetic chemotherapy-photodynamic therapy. *Inorg. Chem.* 62, 1786–1790. doi:10.1021/acs.inorgchem.2c01206
- Wang, Y., Wang, D., Wang, J., Wang, C., Ding, Y., Wang, J., et al. (2022b). Pillar[5]arene-derived covalent organic materials with pre-encoded molecular recognition for targeted and synergistic cancer photo- and chemotherapy. *Chem. Commun.* 58, 1689–1692. doi:10.1039/D1CC07072J
- Webber, M., Appel, E., Meijer, E., and Langer, R. (2016). Supramolecular biomaterials. *Nat. Mater.* 15, 13–26. doi:10.1038/nmat4474
- Wen, Y., Di, X., Chen, Z., Zhang, X., Pei, Z., and Pei, Y. (2024). Supramolecular palladium complexes based on guanidinium pillar[5]arene for cancer therapy. *Chem. Commun.* 60, 12694–12697. doi:10.1039/D4CC04312J
- Wu, J., Tian, J., Rui, L., and Zhang, W. (2018). Enhancing the efficacy of photodynamic therapy (PDT) via water-soluble pillar[5]arene-based supramolecular complexes. *Chem. Commun.* 54, 7629–7632. doi:10.1039/C8CC04275F
- Yang, M., Yang, K., Gao, B., Wang, P., Li, T., Zheng, Y., et al. (2022). A supramolecular nano-delivery system based on AIE PARP inhibitor prodrug and glycosylated pillar[5]arene for drug-resistance therapy. *Chem. Commun.* 58, 11147–11150. doi:10.1039/D2CC04238J
- Yao, Y., Li, Z., and Zhao, R. (2023). Editorial: supramolecular cancer therapeutic biomaterials. *Front. Chem.* 11, 1162103. doi:10.3389/fchem.2023.1162103
- Zhang, H., Zhu, J., Fang, T., Li, M., Chen, G., and Chen, Q. (2022a). Supramolecular biomaterials for enhanced cancer immunotherapy. *J. Mater. Chem. B* 10, 7183–7193. doi:10.1039/D2TB00048B
- Zhang, X., Qi, S., Liu, D., Du, J., and Jin, J. (2022b). PSMA-targeted supramolecular nanoparticles prepared from cucurbit[8]uril-based ternary host-guest recognition for prostate cancer therapy. *Front. Chem.* 10, 847523. doi:10.3389/fchem.2022.847523
- Zhang, Y., Wang, Y., Chen, T., Han, Y., Yan, C., Wang, J., et al. (2023). Pillar[5]arene based water-soluble [3]pseudorotaxane with enhanced fluorescence emission for cell imaging and both type I and II photodynamic cancer therapy. *Chem. Commun.* 59, 8266–8269. doi:10.1039/D3CC01929B
- Zhou, J., Gu, J., Sun, X., Ye, Q., Wu, X., Xi, J., et al. (2024). Supramolecular chiral binding affinity-achieved efficient synergistic cancer therapy. *Adv. Sci.* 11, 2308493. doi:10.1002/advs.202308493